Health Canada has new API guidelines; New Xcelience plant aims for EU market;

> A report says Medicare has the ability to cut off payments for drugs made by compounders under large manufacturing conditions but it is unclear how often it does so. Story

> Health Canada has published new draft guidelines for GMP of active pharmaceutical ingredients and is seeking responses. Release

> Israel-based BiondVax Pharmaceuticals says its manufacturing plant has passed an EU GMP inspection. Release

> Xcelience has opened a new plant in Tampa, FL, and it intends to make clinical trial supplies for markets outside the U.S. there. Story

And Finally... Indian drug manufacturer Aurobindo has told investors that it has upgraded a cephalosporin plant that the FDA placed under an import alert earlier this year and expects it to be approved to again ship APIs to the U.S. by the end of the year. Story

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.